Quantcast

Latest Small interfering RNA Stories

2014-02-04 23:24:31

A team of international researchers say “turning off” the gene for mesothelin slows the spread of mesothelioma and sensitizes cells to cisplatin therapy. Raleigh, NC (PRWEB) February 04, 2014 New research published in the online open-access medical journal PLoS One and reported by Surviving Mesothelioma suggests that “knocking down” mesothelin production with synthetic RNA may offer a novel approach to treating malignant pleural mesothelioma. Mesothelioma is one of several cancers...

2014-01-30 08:30:19

- Arcturus proprietary LUNAR(TM) delivery technology demonstrates exceptional potency in vivo, ED(50) of 0.020 mg/kg SAN DIEGO, Jan. 30, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc. today announced it will present a poster at the Keystone Symposia Conference on RNA Silencing held January 31- February 5, 2014 in Seattle, Washington. The Arcturus poster titled "Design of a Novel, Potent, and Safe RNA Therapeutic Platform Utilizing LUNAR(TM) Delivery Technology" (poster...

2014-01-13 04:21:08

New Preclinical Results in Non-Human Primates Demonstrate Significant and Sustained Reduction of Transthyretin Using its Proprietary LUNARTM Delivery Technology SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNA technologies, today announced its flagship program - an RNAi therapeutic targeting transthyretin (TTR)-mediated amyloidosis. Preclinical non-human primate data will be presented at the Biotech Showcase being held January 13, 2014...

2014-01-10 08:23:49

SEATTLE, Jan. 10, 2014 /PRNewswire/ -- PhaseRx, Inc., an RNA therapeutics company, today announced the appointment of Michael Houston, Ph.D., as its Vice President, Therapeutics Development. (Logo: http://photos.prnewswire.com/prnh/20140110/SF44129LOGO) Dr. Houston brings more than two decades of experience in the manufacturing and development of peptide and oligonucleotide-based therapeutics to PhaseRx. He has directed numerous programs ranging from research to GMP manufacture of...

Study Sheds Light On Treatment For Parkinson's Disease
2013-11-25 07:02:43

NIH/National Institute of Neurological Disorders and Stroke Scientists at the National Institutes of Health have used RNA interference (RNAi) technology to reveal dozens of genes which may represent new therapeutic targets for treating Parkinson's disease. The findings also may be relevant to several diseases caused by damage to mitochondria, the biological power plants found in cells throughout the body. "We discovered a network of genes that may regulate the disposal of dysfunctional...

Researchers Discover Antiviral Response In Mammals Similar To That Found In Plants
2013-10-11 15:22:36

Brett Smith for redOrbit.com - Your Universe Online Previous research has shown that plants and invertebrates use an immune response called the RNA interference (RNAi) pathway to build a weapon against a viral infection. Two new studies from scientists at the University of California, Riverside have found that a similar pathway exists in mammals, but it is typically suppressed by viral proteins. The study researchers said if this suppression could be lifted, it would open the door to a...

2013-07-09 22:54:58

The approach points the way toward new ways to silence malfunctioning genes Silencing genes that have malfunctioned is an important approach for treating diseases such as cancer and heart disease. One effective approach is to deliver drugs made from small molecules of ribonucleic acid, or RNA, which are used to inhibit gene expression. The drugs, in essence, mimic a natural process called RNA interference. In a new paper appearing today online in the journal, ACS Medicinal Chemistry...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.